The POTS, CFS/ME, CRPS determination of patient samples takes place every two weeks in our laboratory. The next diagnosis will be on tuesday, 28th May 2019. Please fill out the request form completely (important: email address and signature) and attach it to your shipment. Thank you very much!Details
Read the abstract of this interesting article: Anti-angiotensin II type 1 receptor (AT1R) antibodies have been associated with allograft rejection. We hypothesized that circulating AT1R antibodies might identify kidney transplant recipients at increased risk of allograft rejection and loss who are not identified by the HLA system. We prospectively enrolled 1845 kidney transplant recipients from…Details
New publication in Frontiers in Bioscience about: Anti-ß1-Adrenoreceptor auto-Antibodies in elderly heart failure patients.
Abstract of the article: An autoimmune reaction directed against the cardiac b1-adrenergic receptor (beta1-ADR) leading to the generation of autoantibodies (AA) against this G-coupled receptor has been described in patients with heart failure (HF). Agonist-like beta1-ADR-AA are associated with morbidity in HF patients and even predict mortality. Standardised and valid diagnostic tools to detect beta…Details
The 10th symposium for Clinical Environmental Medicine will take place in Kiel on 22.02.19 and 23.02.19. The topic is: “Exhaustion as a cardinal symptom of inflammatory and non-inflammatory diseases”. In addition to diagnostics, the focus will be on therapy. FlyerDetails
According to the American Cancer Society ovarian cancer is expected to account for over 22,000 new cancer diagnoses and more than 14,000 deaths in 2018 in the US alone. In early stages of the disease, ovarian cancer is nearly asymptomatic. Hence, a large portion of the patients present with clinically advanced stages of ovarian cancer.…Details
Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More? Cardiovascular diseases are common, accounting for approximately 17.3 million global deaths annually. Substantial evidence exists for numerous risk factors including dyslipidemia, smoking, arterial hypertension, diabetes, and abdominal obesity. Numerous biomarkers have previously been reported in acute coronary syndromes, relating to both inflammation or…Details
Vascular endothelial growth factor (VEGF) plays a central role in tumor growth, metastasis and angiogenesis. Various drugs (such as Avastin (R)) interfere tumor growth at this pathway. CellTrend were the first to describe auto-antibodies against VEGF and measures them with an validated ELISA. This discovery enables new strategies for personalization of tumor therapy and may…Details
CellTrends management system fullfills the requirement for the ISO 13485 standards.
CellTrend received the Patent for DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST EGF-RECEPTOR
The results of the present Examples show that anti-EGFR antibody levels are significant lower in patients with ovarian cancer compared to healthy controls. Furthermore, the levels are significantly higher in patients in which show no relapse after treatment with chemotherapeutic agents or an inhibitor of EGFR activity. Levels of anti-EGFR antibody in patients suffering from…Details